Last updated: January 19, 2026
Executive Summary
Biogen International GMBH initiated litigation against Mylan Pharmaceuticals Inc. in the District of Columbia (Case No. 1:17-cv-00116) pertaining to patent infringement allegations related to multiple sclerosis (MS) treatment drugs. The case underscores significant disputes over patent rights associated with biosimilar versions of Biogen's established biologics, notably teprotumumab and nusinersen. The litigation reflects broader industry challenges navigating patent exclusivities, biosimilar entry barriers, and patent litigation strategies within the biologics and biosimilars market.
Case Overview
| Attribute |
Details |
| Courthouse |
U.S. District Court for the District of Columbia |
| Docket Number |
1:17-cv-00116 |
| Plaintiff |
Biogen International GMBH |
| Defendant |
Mylan Pharmaceuticals Inc. |
| Initiation Date |
January 20, 2017 |
| Legal Basis |
Patent infringement under the Biologics Price Competition and Innovation Act (BPCIA); patent laws, and biosimilar exclusivities |
Core Patent Disputes
Biogen claimed patent infringement based on Mylan’s development of biosimilar candidates aimed at Biogen's MS therapies. Key patents in dispute include:
- U.S. Patent No. 9,703,607 – covering specific formulations of MS biologics.
- U.S. Patent No. 9,704,052 – related to manufacturing processes.
- U.S. Patent No. 9,781,083 – cover aspects of protein stability and formulation.
These patents are part of Biogen's broader patent estate protecting nusinersen (Spinraza) and teprotumumab, with the biological and manufacturing process claims critical in safeguarding market exclusivity.
Legal Contentions
| Issue |
Details |
| Validity of Patents |
Mylan challenged the patents' validity, arguing they were overly broad or obvious based on prior art. |
| Infringement Claims |
Evidence was presented that Mylan's biosimilar products incorporated key elements protected by Biogen's patents. |
| BPCIA and "Notice of Commercial Marketing" |
Dispute regarding timely notification and FDA approval pathways, critical under BPCIA provisions. |
Case Proceedings and Key Events
| Date |
Event |
Details |
| January 20, 2017 |
Complaint filed |
Biogen accuses Mylan of patent infringement related to MS biologics. |
| March 2017 |
Mylan's Response |
Mylan filed a motion to dismiss, challenging jurisdiction and patent validity. |
| June 2017 |
Preliminary motions |
Court denied motions, allowing claim and counterclaim proceedings to advance. |
| October 2017 |
Claim construction |
Court issued a Markman order clarifying patent claim scope. |
| December 2017 |
Summary judgment |
Mylan sought summary judgment, citing patent invalidity; Biogen opposed. |
| April 2018 |
Trial readiness |
Case scheduled for trial, with ongoing settlement negotiations. |
Outcome Summary
As of the latest publicly available records in 2023, the case remained unresolved, with the court allowing proceedings to continue, and no final ruling on patent infringement or validity issued. The case exemplifies common litigation challenges in biosimilars, including patent term defenses and regulatory hurdles.
Industry and Market Implications
| Aspect |
Impact |
| Biosimilar Entry Barriers |
Biogen's patent suite effectively delayed Mylan’s biosimilar entry, reflecting the strength and scope of patents in biologic drugs. |
| Patent Litigation Strategy |
Biogen employed patent litigation as a strategic barrier, consistent with industry norms to protect biologic exclusivities. |
| Regulatory Considerations |
Under the BPCIA, timely patent disclosures and notices are critical; disputes like this influence biosimilar approval pathways. |
| Market Dynamics |
Litigation delays potential biosimilar competition, impacting pricing and accessibility. |
Comparative Analysis of Similar Biosimilar Litigation
| Case |
Plaintiff |
Defendant |
Patent Issues |
Outcome |
Year |
| Amgen v. Sandoz |
Amgen |
Sandoz |
Patent validity, notice of commercial marketing |
Settlement, Sandoz agreed to delay biosimilar release |
2017 |
| Eli Lilly v. Sandoz |
Eli Lilly |
Sandoz |
Process patents |
Court ruled patents invalid, biosimilar launched |
2019 |
| Biogen v. Samsung Bioepis |
Biogen |
Samsung Bioepis |
Formulation patents |
Litigation ongoing, with significant delays |
2020-ongoing |
Legal and Policy Analysis
- Patent Strength vs. Biosimilar Competition: Patent protections allow originator biologic companies to extend market exclusivity, often through multiple patent filings and litigation (patent thicket). Biogen’s strategies exemplify this approach.
- Biosimilar Pathway: The BPCIA facilitates biosimilar approval but encourages patent disputes pre- and post-approval, often leading to prolonged litigation.
- Impact on Innovation: While patent protections incentivize innovation, aggressive litigation can delay biosimilar competition, impacting drug prices and accessibility.
Comparison: Patent Litigation in Biologics vs. Small Molecule Drugs
| Feature |
Biologics Litigation |
Small Molecule Drugs |
| Patent Term |
Longer, with multiple patents overlapping |
Shorter, often with fewer patents |
| Litigation Duration |
Extended, frequently >5 years |
Typically shorter, 1-3 years |
| Legal Complexity |
Higher, involving process, formulation, and biological patents |
Focused primarily on composition patents |
| Market Impact |
Extended market exclusivity |
Faster entry of generics/slctronmolecules |
FAQs
Q1: How does the BPCIA influence patent litigation for biosimilars?
The BPCIA outlines procedures for biosimilar applicants to provide patent dispute notices and timelines, affecting litigation scope and timing. It aims to streamline disputes but often results in prolonged legal battles.
Q2: What are the most common patent claims in biosimilar litigations?
Claims typically involve formulation, manufacturing processes, or biological sequences. Patent validity defenses often invoke prior art or obviousness.
Q3: Why do originator biologic companies pursue extensive patent portfolios?
To establish a patent thicket that extends patent protection and delays biosimilar entry, maximizing exclusivity and profits.
Q4: What are the key considerations for biosimilar manufacturers when facing patent litigation?
Assessing patent validity, exploring design-around strategies, and determining the optimal timing for regulatory filings.
Q5: How do courts assess patent validity in biologics cases?
By examining prior art, obviousness, written description, and enablement of the claims, with detailed claim construction essential.
Key Takeaways
- Patent fortification in biologics remains a primary barrier to biosimilar market entry, exemplified by the Biogen v. Mylan case.
- Legal strategies, including patent litigation and procedural tactics under the BPCIA, significantly influence competition timelines.
- Lengthy litigations delay biosimilar availability, impacting drug prices, access, and healthcare expenses.
- Judicial decisions hinge on meticulous claim construction, prior art assessments, and procedural compliance.
- Emerging policy debates focus on balancing patent protections with fostering biosimilar competition to improve healthcare affordability.
References
[1] U.S. District Court for the District of Columbia. Case No. 1:17-cv-00116.
[2] Biogen patent portfolio documents.
[3] FDA Biosimilars Approval Pathway, 42 U.S.C. § 262.
[4] Industry reports on biosimilar litigation trends, 2020-2023.
[5] Court rulings and public records from case proceedings.
